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Cervical cancer vaccine as a priority of public health 
practices in Iran
Samira Shahbazzadegan1, Malihe Pishvaei2
Dear Chief in Editor
Cervical cancer is the third most common cancer in women. 
In poor countries, it is the second cause of cancer death [1]. 
According to official report of World Health Organization, about 
500,000 new cases of cervical cancer were recorded each year 
that more than half of them are leading to death. 80 percent of 
new cases are occurred in developing countries [2]. The mean 
age of suffered patients is 50-52 years but two picks of disease 
prevalence are 40-39 and 60-64 years. The origin of the cervical 
cancer is the human papillomavirus (HPV), and if it enters to the 
body, the cancer cells were appeared about 12 to 24 months later. 
HPV is a viral disease that directly involved mouth, throat and 
larynges, anus, cervix, and penis [3,4]. Sex is the main cause of 
the transmission of the HPV. Women at any age are in danger. The 
HPV infection could easily transmitted, even with a single sexual 
contact via an asymptomatic carrier. Of all 10 women, 8 people 
are infected with HPV during their lifetime. This infection is also 
sawn in men. Most infections of HPV are self-limited [3]. If the 
virus persist for a long time, it can cause serious problems in the 
skin, especially the genital area. It often has not symptoms, so 
many people are not aware from it [3].
Some strategies exist to prevent cervical cancer, including: rapid 
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and effective treatment of vaginal and cervical 
infections to reduce the transmission rate of 
the virus, use of condom reduces the risk of 
transmission up to 70%, reduce the number of 
sexual partners, and HPV vaccination. HPV 
vaccination can significantly reduce the risk of 
cervical cancer and immunized persons in almost 
all cases [1,3-5]. HPV vaccine is currently being 
administered in many countries according to the 
WHO protocol, and it seems that cancers of the 
cervix will be eradicated over the next 20 to 30 
years. The best time for vaccine injection is the 
ages of 14-26, before the first sexual contact [4]. 
The vaccine is injected into the muscle of the 
arm in three doses. If the vaccine is injected for 
women who had previously sex is also beneficial. 
The duration of immunity from the vaccine 
is unknown, but 5 years has been reported. 
Injecting a vaccine does not mean that a person 
is exempted from routine cervical cancer 
screening because there is still a possibility of 
infection with other HPV genotypes. Till now, 3 
kinds of HPV vaccines have been approved by 
FDA to prevent of this cancer. Their commercial 
names are Gardasil, Cervarix, and Gardasil 9 
[4,5].
Vaccination of cervical cancer is carried out 
in many countries, currently. At present, 
124 countries are used HPV vaccine in their 
vaccination programs [1]. In Iran, the number 
of people infected with the HPV disease and 
was 3.71 million women in 2014 [3], like to 
other types of cancer has grown steadily in 
recent years, while this type of cancer could be 
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controlled and eradicated by vaccination. Now, 
25 to 30 million women over the age of 15 in the 
country are at risk for cervical cancer but it has not 
yet been injected into the country's vaccination 
program [1].
Vaccination coverage for HPV-related cancers 
across the country must be attended by decision 
makers of the Ministry of Health and is a cost 
effective project. Therefore, the prevention 
of cervical cancer is a priority, practical and 
accessible [1,3]. Considering the prevalence 
of cervical cancer in Iranian women, and role 
of unusual sex in the transmission of this virus, 
this is necessary to give more attention by health 
policy makers and responsible organizations to 
include of this vaccine in health care programs.
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